These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 32801445)

  • 21. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
    Gatti M; Andreoni M; Pea F; Viale P
    Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of treatments used in infections caused by gram-positive multiresistant cocci in critically ill patients admitted to the ICU].
    Álvarez-Lerma F; Palomar Martínez M; Olaechea Astigarraga P; Insausti Ordeñana J; López Pueyo MJ; Gracia Arnillas MP; Gimeno Costa R; Seijas Betolaza I
    Rev Esp Quimioter; 2012 Mar; 25(1):65-73. PubMed ID: 22488544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Enterococci With Special Resistance Patterns - Epidemiology, Hygiene and Therapy].
    Mischnik A; Werner G; Bender J; Mutters NT
    Dtsch Med Wochenschr; 2019 Apr; 144(8):553-560. PubMed ID: 30986864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of Gram-positive cocci infection and the therapeutic effect after liver transplantation.
    Wu X; Wu L; Shu L; Xie C; Wan Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 May; 48(5):707-715. PubMed ID: 37539573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Photosensitivity During Quinolone Therapy in Diabetic Foot Patients May Falsely Indicate Treatment Failure.
    Loupa CV; Meimeti E; Voyatzoglou ED; Donou A; Kalantzi S; Konsta E
    Int J Low Extrem Wounds; 2023 Mar; 22(1):117-121. PubMed ID: 32975143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019-2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
    Tsai HY; Lee YL; Liu PY; Lu MC; Shao PL; Lu PL; Cheng SH; Ko WC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Lee WS; Shi ZY; Chen YS; Wang FD; Tseng SH; Chen YH; Sheng WH; Lee CM; Chen YH; Liao CH; Hsueh PR
    Int J Antimicrob Agents; 2021 Jul; 58(1):106353. PubMed ID: 33961991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
    Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
    Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
    Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin.
    Jenkins I
    J Hosp Med; 2007 Sep; 2(5):343-4. PubMed ID: 17935250
    [No Abstract]   [Full Text] [Related]  

  • 32. Dalbavancin for the management of osteomyelitis: a major step forward?
    Almangour TA; Alhifany AA
    J Antimicrob Chemother; 2020 Oct; 75(10):2717-2722. PubMed ID: 32457989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective.
    Zinzi D; Vlachaki I; Falla E; Mantopoulos T; Nathwani D
    Eur J Health Econ; 2022 Nov; 23(8):1371-1381. PubMed ID: 35113269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
    Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
    J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections.
    Petrakis V; Panagopoulos P; Papanas N
    Int J Low Extrem Wounds; 2020 Sep; 19(3):236-241. PubMed ID: 32500744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful Outpatient Treatment of Severe Diabetic-Foot Myositis and Osteomyelitis Caused by Extensively Drug-Resistant Enterococcus faecalis with Teicoplanin plus Rifampicin: A Case Report.
    Papaetis GS; Doukanaris PT; Stylianou ES; Neofytou MS
    Am J Case Rep; 2023 Nov; 24():e941337. PubMed ID: 37910441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria.
    Eliopoulos GM
    J Infect; 2009 Sep; 59 Suppl 1():S17-24. PubMed ID: 19766885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The current and future off-label uses of dalbavancin: a narrative review.
    De Vito A; Fiore V; Colpani A; Zauli B; Fanelli C; Tiseo G; Occhineri S; Babudieri S; Falcone M; Madeddu G
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1222-1238. PubMed ID: 36808371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the treatment of infections due to resistant Staphylococcus aureus.
    Anstead GM; Owens AD
    Curr Opin Infect Dis; 2004 Dec; 17(6):549-55. PubMed ID: 15640709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
    Manfredi R
    Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.